Formalin-Fixed Paraffin-Embedded Tissue News
-
New White Paper by ProPath Supports Superiority of Dako`s HER2 IQFISH pharmDx Kit
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced positive findings in a white paper by ProPath Services comparing Dako's HER2 IQFISH pharmDx kit with Abbott's PathVysion HER-2 DNA Probe kit. ProPath Services is an independent anatomic pathology laboratory headquartered in Dallas, Texas. The white paper, written by Debra S. Cohen, BS, ...
-
Agilent Technologies Introduces IQFISH FFPE Buffer, Enabling One-Hour Hybridization of FFPE Tissue Samples
Agilent Technologies Inc. (NYSE: A) today introduced the IQFISH FFPE Hybridization buffer, which enables one-hour hybridization for FISH processing on formalin fixed paraffin embedded (FFPE) tissue samples. The IQ technology, originally developed by Dako, was previously available only to anatomic pathology labs. Now, with the IQFISH FFPE Hybridization buffer offered as a standalone product, ...
-
Application of Whole-Genome Sequencing in Older Esophageal Carcinoma FFPE Tissues Reveals Novel Insights
Collection of fresh-frozen tumor samples is often challenging or infeasible, leading many studies to rely on formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. Because these tissues are often paired with a great deal of clinical and outcome data, analysis of these archives has the potential to lead to major advances in cancer treatment and prevention. Whole-genome sequencing (WGS) ...
-
xCures and mProbe partner to help cancer patients determine optimal treatments
xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the diagnosis, prevention, and treatment of complex diseases such as cancer. As the knowledge of cancer and its treatments advance, it is ever ...
By xCures
-
Thermo Fisher Scientific to Co-develop a Global Companion Diagnostic for Low-grade Glioma with Agios Pharmaceuticals
Thermo Fisher Scientific today announced that it has expanded its strategic partnership with Agios Pharmaceuticals by adding the co-development of a second companion diagnostic (CDx) for oncology to their existing agreement. The CDx will leverage the Oncomine Precision Assay, which runs on the new Ion Torrent Genexus System, and will be used globally to identify low-grade glioma (LGG) patients ...
-
Cancer Genomic Screening Program LC-SCRUM-Asia Adopts Latest Thermo Fisher Scientific NGS Solutions
LC-SCRUM-Asia, a leading cancer genomic screening program, has selected Thermo Fisher Scientific's Ion Torrent Genexus System* and Oncomine Precision Assay*, a pan-cancer panel, to advance precision medicine in Asia. The next-generation sequencing (NGS) solutions will be used in two prospective, observational projects to support the development of future therapeutics and diagnostics for non-small ...
-
Amerigo Scientific Launches New Polyclonal Antibody to Human Blood Coagulation Factor XIII
Amerigo Scientific, a distributor focused on providing critical products and services to the biomedical and life science communities, recently announced the launch of its new polyclonal antibody to human blood coagulation factor XIII to support researchers in life science fields for the detection of blood coagulation factor XIII. This antibody is used for research only, not for human, therapeutic ...
-
FDA Approves NGS-Based Companion Diagnostic for EGFR Exon20 Insertion Mutant Non-Small Cell Lung Cancer Tumor Tissue
The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients whose tumors carry epidermal growth factor receptor (EGFR) Exon20-insertion mutations for potential treatment with RYBREVANT (amivantamab-vmjw)*, Janssen Biotech, Inc.'s ...
-
Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Hengrui Therapeutics, Inc.
Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Hengrui Therapeutics, Inc. (HTI), a U.S. subsidiary of Chinese pharmaceutical company Jiangsu Hengrui Medicine Co., Ltd. (JHM), to develop a CDx that will leverage the Oncomine Precision Assay, which runs on the new Ion Torrent Genexus System. Once commercialized, the CDx will be used to identify non-small cell lung ...
-
FoundationOne®CDx Receives FDA Approval as a Companion Diagnostic for BRAF Inhibitor Therapeutics in Melanoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for two groups of current and future FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies targeting BRAFV600E and BRAF/MEK inhibitor combination ...
-
Foundation Medicine Now an In-Network Provider for Humana Military and Health Net Federal Services
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced that the company has signed agreements for in-network provider status with Humana Military and Health Net Federal Services, which administer the TRICARE health program for military members, retirees and their families (TRICARE).1,2 TRICARE is one of the largest health plans in the United States with 9.6 million ...
-
Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly’s Pipeline Programs
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced a collaboration with Eli Lilly and Company (Lilly) for the development of Foundation Medicine’s tissue- and blood-based assays as companion diagnostics for RETEVMO® and other therapies in Loxo Oncology at Lilly’s pipeline. The partnership will initially explore the use of FoundationOne®CDx for adult ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you